74 related articles for article (PubMed ID: 16823497)
41. Molecule of the Month.
Drug News Perspect; 2002 Oct; 15(8):527. PubMed ID: 12677191
[No Abstract] [Full Text] [Related]
42. Molecule of the Month.
Drug News Perspect; 2002 Sep; 15(7):460. PubMed ID: 12677182
[No Abstract] [Full Text] [Related]
43. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
[No Abstract] [Full Text] [Related]
44. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes.
He YL; Horowitz A; Watson CE; Foley JE; Sallas W; Ligueros-Saylan M
J Clin Pharmacol; 2007 Jan; 47(1):127-31. PubMed ID: 17192511
[No Abstract] [Full Text] [Related]
45. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
[TBL] [Abstract][Full Text] [Related]
46. Molecule of the month. Vildagilptin.
Drug News Perspect; 2006 May; 19(4):228. PubMed ID: 16823497
[No Abstract] [Full Text] [Related]
47. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
[No Abstract] [Full Text] [Related]
48. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
49. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
50. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
51. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
